Teva Pharmaceuticals (NYSE:TEVA) said today that the FDA approved its Qvar RediHaler breath-actuated inhaler for the maintenance treatment of asthma in patients ages 4 and older.
The device, which is not indicated for acute bronchospasm, is slated to become commercially available during the first quarter of 2018.
Get the full story at our sister site, Drug Delivery Business News.
The post Teva wins FDA nod for Qvar RediHaler device appeared first on MassDevice.